文献速递围术期管理与 ERAS急腹症与外科感染

美国手术后阿片类药物处方及新发持续使用趋势

Trends in Opioid Prescribing and New Persistent Opioid Use After Surgery in the United States.
PubMed 文献 · Ann Surg · 2024-08-01

该回顾性队列研究利用2013至2021年多付款方理赔数据,纳入989354例接受17种常见手术的阿片初治成人患者,评估术后阿片处方量与新发持续使用趋势。结果显示调整后初始处方量从282 mg OME降至164 mg OME,新发持续使用率从2.7%降至1.1%。

要点

  • 术后初始阿片处方量每增加30 OME,新发持续使用风险增加3.1%。
  • 术前非阿片类受控物质处方及骨科手术是新发持续使用的预测因素。
  • 十年间阿片处方量与新发持续使用率均下降,提示阿片管理措施有效。

核心结论

  • 过去十年手术后阿片处方量和新发持续使用均下降,提示阿片管理实践对长期阿片使用风险有有利影响。

研究设计与样本

  • 回顾性队列研究,利用Health Care Cost Institute多付款方理赔数据,纳入2013至2021年接受17种常见手术的阿片初治私保成人患者989354例。

主要发现

  • 调整后初始阿片处方量从282 mg OME降至164 mg OME,减少118 mg OME(95% CI: 116-120)。
  • 调整后新发持续阿片使用率从2013年2.7%(95% CI: 2.6%-2.8%)降至2021年1.1%(95% CI: 1.0%-1.2%)。
  • 初始阿片处方量每增加30 OME,新发持续使用增加3.1%。
  • 术前31-365天非阿片类受控物质处方aOR=1.78(95% CI: 1.70-1.86),0-30天aOR=2.71(95% CI: 2.59-2.84)。
  • 骨科手术预测新发持续使用:全膝关节置换aOR=3.43(95% CI: 3.15-3.72),肩关节镜aOR=2.39(95% CI: 2.24-2.56)。

临床怎么用

  • 术后应尽量减少初始阿片处方量,以降低新发持续阿片使用风险。
  • 对术前使用非阿片类受控物质及接受骨科手术的患者,应加强术后阿片使用监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To define recent trends in opioid prescribing after surgery and new persistent opioid use in the United States. BACKGROUND: New persistent opioid use after surgery among opioid-naive individuals has emerged as an important postoperative complication. In response, initiatives to promote more appropriate postoperative opioid prescribing have been adopted in recent years. However, current estimates of opioid prescribing and new persistent opioid use following surgery remain unknown. METHODS: A retrospective cohort study of opioid-naive privately insured adult patients undergoing 17 common surgical procedures between 2013 and 2021 was conducted utilizing multi-payer claims data from the Health Care Cost Institute (HCCI). Initial opioid prescription size in oral morphine equivalents (OMEs) and new persistent opioid use were the outcomes of interest. Trends in opioid prescribing and rates of new persistent opioid use were evaluated across the study period. Mixed effects logistic regression was performed to evaluate independent predictors of new persistent opioid use while adjusting for patient-level factors and year. RESULTS: Among 989,354 opioid-naive individuals, the adjusted initial opioid prescription size decreased from 282 mg OME to 164 mg OME, a reduction of 118 mg OME (95% CI: 116-120). The adjusted incidence of new persistent opioid use decreased from 2.7% in 2013 (95% CI: 2.6%-2.8%) to 1.1% in 2021 (95% CI: 1.0%-1.2%). For every 30 OME increase in initial opioid prescription size, new persistent opioid use increased by 3.1%. Other predictors of new persistent opioid use included preoperative nonopioid controlled substances fills [31-365 days: adjusted odds ratio (aOR)=1.78, 95% CI: 1.70-1.86; 0-30 days: aOR=2.71, 95% CI: 2.59-2.84] and undergoing orthopedic procedures [total knee arthroplasty (aOR=3.43, 95% CI: 3.15-3.72); shoulder arthroscopy (aOR=2.39, 95% CI: 2.24-2.56)]. CONCLUSIONS: Both opioid prescription size after surgery and new persistent opioid use decreased over the last decade, suggesting that opioid stewardship practices had favorable effects on the risk of long-term opioid use.

来源:Ann Surg,查看原文。版权归原作者所有。

引用

  1. Luby AO, Alessio-Bilowus D, Hu HM, et al. Trends in Opioid Prescribing and New Persistent Opioid Use After Surgery in the United States. Ann Surg. 2024. PMID: 39087325. doi:10.1097/SLA.0000000000006461

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。